UNICREDIT BANK/CALL/BIOGEN IDEC/220/0.1/19.03.25 | Real-time BOERSE MUENCHEN 01:10:44 03/07/2024 pm IST | ||
| 3.18 EUR | 0.00% |
|
| Current month | -5.92% | ||
| 1 month | -1.85% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
| Date | Price | Change |
|---|---|---|
| 03/24/03 | 3.18 | 0.00% |
| 02/24/02 | 3.18 | -9.40% |
| 01/24/01 | 3.51 | +3.85% |
| 28/24/28 | 3.38 | +0.60% |
| 27/24/27 | 3.36 | +9.45% |
Real-time BOERSE MUENCHEN
Last update July 03, 2024 at 01:10 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | 
UniCredit
|
| WKN | HD4FKR |
| ISIN | DE000HD4FKR1 |
| Date issued | 08/04/2024 |
| Strike | 220 $ |
| Maturity | 19/03/2025 (260 Days) |
| Parity | 10 : 1 |
| Emission price | 2.44 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.94 € |
|---|---|
| Lowest since issue | 1.84 € |
| Spread | 0.08 € |
| Spread % | 2.49% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
35
Last Close Price
228.8
USD
Average target price
283.2
USD
Spread / Average Target
+23.75%
- Stock Market
- Warrants
- Warrant
